Skip to main content

Table 1 List of clinical trials included in the analysis

From: Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Study Phase Histology Masking No. patients Treatment arms
CA209-067 [8] 3 Melanoma Double-blind 945 Nivolumab + Ipilimumab vs Nivolumab vs Ipilimumab*
CA209-227 [10] 3 Nonsmall cell lung cancer (NSCLC) Open-label 1189 Nivolumab + Ipilimumab vs chemotherapy vs Nivolumab*
IFCT-1501 MAPS2 [11] 2 Mesothelioma Open-label 108 Nivolumab + Ipilimumab vs nivolumab
Alliance A091401 [12] 2 Sarcoma Open-label 85 Nivolumab + Ipilimumab vs nivolumab*
CA209-032 [13] 1/2 Small cell lung cancer (SCLC) Open-label 196 Nivolumab + Ipilimumab and Nivolumab**
CA209-032 [14] 1/2 Gastric Open-label 108 Nivolumab + Ipilimumab and Nivolumab**
CA209-032 [15] 1/2 Bladder Open-label 196 Nivolumab + Ipilimumab vs nivolumab
  1. *Nivo 3 mg + IPI 1 mg. **Nivo 1 mg + IPI 3 mg